carbamates has been researched along with td-4208 in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 8 (42.11) | 2.80 |
| Authors | Studies |
|---|---|
| Hegde, SS; Jaw-Tsai, S; Ji, Y; Martin, WJ; McNamara, A; Obedencio, GP; Pulido-Rios, MT | 1 |
| Barnes, CN; Bourdet, DL; Haumann, B; Moran, EJ; Nicholls, A; Potgieter, P; Quinn, D; Singh, D; Yates, W | 1 |
| Foley, JJ; Hegde, SS; Hunsberger, GE; Jasper, JR; Ji, Y; Lee, T; Luttmann, MA; Mammen, MM; Pulido-Rios, MT; Steinfeld, T | 1 |
| Heo, YA | 1 |
| Li, F; Yang, J | 1 |
| Barnes, CN; Crater, G; Dean, L; Donohue, JF; Haumann, B; Kerwin, E; Moran, EJ; Pendyala, S; Sethi, S | 2 |
| Barnes, CN; Bourdet, D; Crater, G; Donohue, JF; Feldman, G; Pendyala, S; Sethi, S | 1 |
| Hussar, DA | 1 |
| Barnes, CN; Borin, MT; Bourdet, DL; Darpo, B; Pendyala, S; Xue, H | 1 |
| Barnes, CN; Borin, MT; Bourdet, DL; Lo, A; Pendyala, S | 1 |
| Khan, A; Lal, C | 1 |
| Clark, CM; Jacobs, DM; Sethi, S | 1 |
| Tutalo, R; Wilkinson, J | 1 |
| Antoniu, SA; Grigore, M; Mihaltan, F; Rajnoveanu, R; Ulmeanu, R | 1 |
| Barnes, CN; Crater, GD; Donohue, JF; Haumann, B; Kerwin, E; Moran, EJ | 1 |
| Borin, MT; Bourdet, DL; Lo, A | 1 |
| Hvisdas, C | 1 |
6 review(s) available for carbamates and td-4208
| Article | Year |
|---|---|
Revefenacin: First Global Approval.
Topics: Administration, Inhalation; Adult; Aged; Benzamides; Bronchodilator Agents; Carbamates; Drug Approval; Humans; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; United States; United States Food and Drug Administration | 2019 |
Revefenacin for the treatment of chronic obstructive pulmonary disease.
Topics: Acetylcholine; Animals; Benzamides; Bronchodilator Agents; Carbamates; Forced Expiratory Volume; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2019 |
Revefenacin (Yupelri) for COPD.
Topics: Administration, Inhalation; Benzamides; Bronchodilator Agents; Carbamates; Humans; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2019 |
Emerging Treatments for COPD: Evidence to Date on Revefenacin.
Topics: Benzamides; Carbamates; Drug Administration Schedule; Forced Expiratory Volume; Humans; Medication Adherence; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2020 |
Revefenacin for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Benzamides; Carbamates; Clinical Trials as Topic; Humans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive | 2020 |
Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Benzamides; Bronchodilator Agents; Carbamates; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2021 |
6 trial(s) available for carbamates and td-4208
| Article | Year |
|---|---|
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Topics: Administration, Inhalation; Aged; Benzamides; Bronchodilator Agents; Carbamates; Cross-Over Studies; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Ipratropium; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Spirometry; Time Factors | 2018 |
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Benzamides; Bronchodilator Agents; Carbamates; Case-Control Studies; Cholinergic Antagonists; Disease Progression; Drug Therapy, Combination; Drug Tolerance; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Safety; Severity of Illness Index; Tiotropium Bromide; Vital Capacity | 2019 |
Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Benzamides; Bronchodilator Agents; Carbamates; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Tiotropium Bromide | 2019 |
Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
Topics: Adolescent; Adult; Benzamides; Carbamates; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Healthy Volunteers; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Muscarinic Antagonists; Young Adult | 2020 |
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
Topics: Aged; Benzamides; Bronchodilator Agents; Carbamates; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome | 2019 |
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Benzamides; Bronchodilator Agents; Carbamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Time Factors | 2020 |
7 other study(ies) available for carbamates and td-4208
| Article | Year |
|---|---|
In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.
Topics: Acetylcholine; Administration, Inhalation; Animals; Benzamides; Bronchoconstriction; Bronchodilator Agents; Carbamates; Dogs; Dose-Response Relationship, Drug; Glycopyrrolate; Lung; Male; Methacholine Chloride; Muscarinic Antagonists; Pilocarpine; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptor, Muscarinic M3; Salivation; Scopolamine Derivatives; Tiotropium Bromide | 2013 |
Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.
Topics: Administration, Inhalation; Animals; Benzamides; Bronchi; Carbamates; Guinea Pigs; Humans; Muscarinic Antagonists; Nebulizers and Vaporizers; Rats; Recombinant Proteins; Trachea | 2018 |
New Drugs 2019, part 3.
Topics: Aminoquinolines; Antibodies, Monoclonal, Humanized; Benzamides; Cannabidiol; Carbamates; Dibenzothiepins; Drug Approval; Humans; Morpholines; Oxazines; Pyridines; Pyridones; Thiepins; Triazines; United States; United States Food and Drug Administration | 2019 |
Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Carbamates; Female; Hepatic Insufficiency; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Renal Insufficiency; Severity of Illness Index; Young Adult | 2019 |
Revefenacin (Yupelri) for the Treatment of Chronic Obstructive Pulmonary Disease.
Topics: Benzamides; Bronchodilator Agents; Carbamates; Humans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive | 2020 |
Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease.
Topics: Benzamides; Carbamates; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2020 |
Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Bronchodilator Agents; Carbamates; Female; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive | 2021 |